The Untapped Potential of India’s AYUSH Exports: A Story of Dominance, Neglect, and Opportunity
India’s traditional medicine systems, collectively known as AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy, plus the Tibetan Sowa-Rigpa), are a treasure trove of cultural heritage and economic potential. Yet, as I delve into the export data, one thing immediately stands out: the staggering imbalance in how these systems are represented on the global stage. What makes this particularly fascinating is how a single product, psyllium husk, dominates over half of India’s AYUSH and herbal exports, while entire therapeutic systems like Unani and Siddha barely register. This raises a deeper question: Are we truly leveraging the richness of AYUSH, or are we missing the forest for the trees?
The Psyllium Husk Phenomenon: A Double-Edged Sword
Psyllium husk, a botanical commodity, accounts for a jaw-dropping 55.47% of India’s AYUSH exports. From my perspective, this is both impressive and alarming. On one hand, it’s a testament to India’s prowess in cultivating and exporting high-demand botanical products. On the other hand, it highlights a dangerous concentration risk. If you take a step back and think about it, relying so heavily on one product leaves the entire sector vulnerable to market fluctuations. What happens if global demand for psyllium husk drops? The entire export basket could crumble.
What many people don’t realize is that this dominance isn’t just about psyllium husk. Ayurvedic medicaments, while a significant player at 27.30% of exports, are the only system-designated products holding their ground. The rest of the AYUSH systems—Unani, Siddha, and Homoeopathy—are virtually invisible in international markets. Personally, I think this is a missed opportunity. These systems have unique therapeutic offerings that could appeal to global consumers, yet they remain under-leveraged.
The Decline of Homoeopathy and the Marginalization of Unani and Siddha
One detail that I find especially interesting is the consistent decline of Homoeopathic exports, which peaked at ₹24.79 Cr in 2021–22 and plummeted to ₹13.96 Cr by 2025–26. What this really suggests is that Homoeopathy, despite its global recognition, is struggling to find its footing in the export market. Similarly, Unani and Siddha exports are marginal at best, with Siddha exports falling to a mere ₹1.51 Cr in 2024–25 before a slight recovery.
In my opinion, this isn’t just a numbers problem—it’s a branding and marketing issue. Ayurveda has successfully positioned itself as a holistic wellness system, but the other AYUSH systems lack the same global appeal. If you ask me, this is where India needs to invest: in promoting these systems as unique, culturally rich alternatives to mainstream medicine.
Destination Diversification: A Lesson from China and the US
Another critical insight from the data is the need for destination diversification. Germany, Sweden, and the USA dominate exports of products like psyllium seeds, but the sharp decline in China’s AYUSH imports (-74.4% from its peak) and the sudden drop in US imports (-21.2% in 2025–26) should serve as a wake-up call. What this really highlights is the volatility of relying on a handful of markets.
From my perspective, India needs to explore emerging markets like South Korea, Australia, and Mexico more aggressively. These countries have shown significant traction for AYUSH products, and diversifying export destinations could mitigate risks associated with demand shifts in traditional markets.
The Broader Implications: Cultural Heritage and Economic Growth
If you take a step back and think about it, AYUSH isn’t just an export category—it’s a cultural legacy. Ayurveda, Unani, Siddha, and Homoeopathy are more than just therapeutic systems; they’re a testament to India’s ancient wisdom. Yet, the data suggests we’re not doing enough to preserve and promote this heritage.
What this really implies is that India’s AYUSH sector is at a crossroads. On one hand, it has the potential to become a global leader in traditional medicine. On the other hand, it risks becoming a one-trick pony, reliant on a few products and markets. Personally, I think the solution lies in a multi-pronged approach: diversify the product basket, invest in marketing the lesser-known systems, and strengthen trade data granularity to make informed decisions.
Final Thoughts: A Call to Action
As I reflect on the data, one thing is clear: India’s AYUSH exports are a story of untapped potential. The dominance of psyllium husk and Ayurvedic medicaments is impressive, but it’s also a reminder of how much more we could achieve. What makes this particularly fascinating is the opportunity to not just grow economically, but to share India’s cultural heritage with the world.
In my opinion, the time is now to rethink our approach. Diversify, promote, and innovate—these should be the watchwords for India’s AYUSH sector. If we get this right, we’re not just boosting exports; we’re preserving a legacy. And that, to me, is what makes this journey so compelling.
